Pharmaron Beijing Co., Ltd.
300759
株式のランク
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
株価
$5.58
時価総額
$8.24B
変化（1日）
-3.77%
変化（1年）
28.36%
国
CN
取引 Pharmaron Beijing Co., Ltd. (300759)
カテゴリー
Healthcare
Pharmaron Beijing Co., Ltd.（300759）の利益
Jun 2026 時点の利益 TTM: $303.40M
Pharmaron Beijing Co., Ltd. の最新の財務報告によると、同社の現在の利益は $303.40M です。2024 年には $286.51M の利益を上げ、これは 2023 年の利益 $259.64M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Pharmaron Beijing Co., Ltd. の利益の推移（2014 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $303.40M | 10.98% |
| 2025 | $273.38M | -4.58% |
| 2024 | $286.51M | 10.35% |
| 2023 | $259.64M | 7.48% |
| 2022 | $241.58M | -19.65% |
| 2021 | $300.66M | 48.87% |
| 2020 | $201.96M | 122.33% |
| 2019 | $90.84M | 59.17% |
| 2018 | $57.07M | 33.32% |
| 2017 | $42.81M | 38.55% |
| 2016 | $30.90M | 129.26% |
| 2015 | $13.48M | 188.75% |
| 2014 | $4.67M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 1,638.58% |
US
|
|
| $-3.09B | -1,117.46% |
US
|
|
| $-4.02B | -1,423.72% |
AU
|
|
| $2.85B | 837.94% |
BE
|
|
| $1.95B | 542.93% |
NL
|
